[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lindenwood University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":220},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,62,89,114,137,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100634969","a-pilot-study-to-evaluate-the-ability-of-lactoferrin-to-modulate-iron-homeostasis-and-exercise-performance-in-exercising-females-100634969",false,"NCT07546591","A Pilot Study to Evaluate the Ability of Lactoferrin to Modulate Iron Homeostasis and Exercise Performance in Exercising Females","A Pilot Study to Evaluate the Ability of Lactoferrin to Modulate Iron Homeostasis and Exercise Performance in Exercising Females With Compromised Iron Status","EFF","Inclusion Criteria:\n\n* Women, 18 - 45 years of age\n* No changes in hormonal contraception use in the past 6 months\n* Has a regular menstrual cycle defined as five out of the past six months\n* Engaging in ≥5 hours per week of structured endurance exercise (e.g., running, cycling, swimming, rowing) for the past ≥6 months, with ≥3 sessions per week at moderate-to-vigorous intensity (≥70% HRmax or RPE ≥13).\n* Training must be consistent, with no interruptions \\>2 consecutive weeks in the past 6 months and performed with the purpose of improving performance or preparing for a competition or personal goal.\n* Exhibit some degree of compromised iron status as depicted by serum ferritin levels below 30 ug\u002FL\n* Participation in at least one organized endurance event (e.g., races, competitions, or matches) at the recreational, sub-elite, or elite level, or be actively training for a planned competition within the next 6 months.\n* Generally healthy and free of diseases or disorders that impact functioning of the gastrointestinal system.\n* No recent or acute infection in the past 30 days and no chronic systemic illness\n* No psychiatric condition that, in the investigator's judgment, would impair consent capacity, protocol adherence, or valid completion of questionnaires.\n* If psychiatric medication is used: stable regimen for ≥3 months with no anticipated changes during the study\n* Body mass index (BMI) 18.5 to 32.5 kg\u002Fm2 (Inclusive)\n* Non-smoker\n* Agrees to not use any new vitamin, mineral, or dietary supplement product until after study completion and to not take any vitamins, minerals or dietary supplements 24 hours prior to any of the study visits.\n* Willing and able to maintain consistent diet and physical activity habits\n* Participants who become pregnant during the course of the study will be removed from participation\n* Willing and able to provide consent and comply with the protocol\n* Able to read and understand English at the 6th-grade level and sign the informed consent to participate in the study\n\nExclusion Criteria:\n\n* History of any food allergies or intolerances that could impact digestive outcomes and history of irritable bowel syndrome, inflammatory bowel disease (Crohn's, ulcerative colitis, celiac), gastroparesis, chronic constipation or diarrhea requiring medication, or GI surgery\n* Has any of the following medical conditions: bleeding disorders, active heart or cardiovascular disease, uncontrolled high blood pressure (≥ 140\u002F90 mmHg), renal or hepatic impairment\u002Fdisease, Type I or II diabetes, any neurologic disease or disorder that may impact cognition or mood, unstable thyroid disease, chronic inflammatory conditions, immune disorders (such as HIV\u002FAIDS), or any medical condition deemed exclusionary by the Principal Investigator (PI)\n* Acute illness or infection within the past 30 days\n* History of cancer (except localized skin cancer without metastases) within 5 years prior to screening.\n* Recently started taking (within the past 90 days or has had their dosage adjusted in the past 90 days) antihypertensives, hypoglycemic medications, GLP1 agonists of any class or type, stimulatory asthma medications, or any other prescription or over-the-counter medication that confound the outcomes measured in this study\n* Habitual use of anti-inflammatory medications for 30 days prior to providing\n* Current or past diagnosis of bipolar I\u002FII disorder, schizophrenia spectrum or other psychotic disorder; psychiatric hospitalization, suicidal ideation, attempt, or self-harm behavior in the past 12 months\n* Initiation, discontinuation, or dose change of any psychotropic medication within the past 3 months, including antidepressants, anxiolytics, antipsychotics, mood stabilizers, stimulants, or sedative-hypnotics\n* Subject has an allergy to any ingredients in the study product\n* Subject has a history of drug or alcohol abuse in the past 12 months\n* Excessive alcohol intake defined as greater than 7 drinks\u002Fweek or binge episodes\n* Any condition or abnormality that in the expert opinion of the PI, participation in the study would compromise the safety of the subject or the quality of the study data.\n* Participating in or has participated in another research study within 30 days prior to the screening visit that could confound outcomes\n* Currently pregnant or lactating",true,"FEMALE","18 Years","45 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","This randomized, double-blind, active-controlled trial will evaluate the effects of human lactoferrin supplementation combined with low-dose iron on iron status, aerobic performance, and lactate metabolism in exercising women with low ferritin. Approximately 30 healthy, menstruating women aged 18-45 years with serum ferritin \\\u003C35 µg\u002FL will be enrolled in an 8-week intervention. Participants will be stratified by baseline ferritin status and randomized to receive 100 mg lactoferrin + 5 mg iron, 300 mg lactoferrin + 5 mg iron, or placebo + 5 mg iron daily.\n\nPrimary outcomes include changes in ferritin and hematological parameters. Secondary outcomes include VO₂peak, time to exhaustion, and blood lactate responses during standardized treadmill testing.\n\nThis study will determine whether lactoferrin enhances iron homeostasis and improves physiological and performance outcomes in exercising women with low iron stores.",[29,30,31,32],"Iron Deficiencies","Low Ferritin","Iron Deficiency","Exercise Performance of Fit Athletes",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48],"lactoferrin","effera","iron supplementation","iron metabolism","ferritin","aerobic performance","vo2peak","endurance exercise","time to exhaustion","lactate metabolism","female athletes","exercising females","menstruating women","iron bioavailability","nutritional supplementation","RECRUITING","2026-04-22",{"date":52,"type":53},"2026-04-27","ACTUAL",{"date":55,"type":23},"2026-04-30",{"date":57,"type":23},"2027-04-30",{"name":59,"class":60},"Lindenwood University","OTHER",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":17,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":24,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":61},"100631610","dose-response-impact-of-geranylgeraniol-gg-supplementation-on-muscle-health-100631610","NCT07502924","Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health","Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscular Strength, Body Composition, Sex Steroid Hormones and CoQ10 Levels in Healthy Men and Women","GGE","Inclusion Criteria:\n\n* Between 30 and 60 years old.\n* Body mass index values will range from \\>18.5 and \\\u003C29.9 kg\u002Fm2\n* Subject agrees to maintain their existing dietary patterns throughout the study period.\n* Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.\n* Is physically active, defined as at least 30 min of moderate exercise on at least 4 days a week.\n* Avoid consumption of pomegranate juice and avoid consumption of CoQ10, vitamin B3 and its precursors, L-carnitine, MK-4\n* Subject is willing and able to comply with the study protocol.\n* Subject has given voluntary, written, informed consent to participate in the study.\n\nExclusion Criteria:\n\n* BMI \\\u003C18.5 or \\> 29.9 kg\u002Fm2\n* Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease, kidney disease, renal failure, or has dialysis performed on regular intervals, Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL), thyroid disease, liver disease or some form of clinically diagnosed hepatic impairment, immune disorder (i.e., HIV\u002FAIDS), or neurological condition or disease.\n* Diagnosed with any affective disorder or other psychiatric disorder that required hospitalization in the prior year.\n* History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n* Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)\n* Genetic musculoskeletal and neurologic disorder known to affect skeletal muscle metabolism\n* Has donated blood in past 60 days\n* Diagnosed with or being treated for any endocrinological disorder and\u002For taking hormone boosting supplements (e.g. herbs) or hormone replacement therapy (prescribed\u002Fdoctor ordered or not)\n* Had CoQ10 supplement in past 30 days. Had steroid medication one month before starting the study\n* Currently prescribed for the first time a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) and\u002For a hypertension medication (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, - Vasodilators, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months\n* Current smoker (average of \\> 1 pack per week within the past 3 months) or has quit within the past six months. This includes all forms of nicotine\n* Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to impact energy expenditure or weight loss (caffeine doses \\\u003C300 mg\u002Fday is permissible)\n* Women with a history of hormone-related conditions such as endometriosis, fibroids, polycystic ovary syndrome\n* Women who are pregnant, planning to become pregnant, or lactating currently or within the past six months\n* Have a known sensitivity or allergy to any of the study products\n* History of alcohol or substance abuse in the 12 months prior to screening\n* Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol\n* Has participated in other clinical trials focused on physical and muscle performance within the last year\n* They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study\n* Individuals who regularly compete as part of sanctioned athletic activities or those individuals who regularly train more than 360 minutes of exercise per week\n* Recent history (\\\u003C3 months) of exercise training or weight loss (\\> 5%)\n* Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data","ALL","30 Years","60 Years",{"count":74,"type":23},70,[26],"This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group trial lasting 8 weeks.\n\nParticipants will be assigned to receive either placebo, 150 mg GG, or 300 mg GG daily. Outcome measures will be assessed at baseline, week 4, and week 8 and include maximal strength (1RM bench press and leg press), fat-free mass, muscular endurance, aerobic capacity (VO2peak), and circulating biomarkers related to metabolism and health.",[78,79,80],"Muscle Health","Muscle Strength","Body Composition","2026-03-25",{"date":83,"type":53},"2026-03-31",{"date":85,"type":53},"2025-03-03",{"date":87,"type":23},"2026-08-01",{"name":59,"class":60},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":17,"sex":70,"minAge":19,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":24,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":61},"100622774","evaluating-the-ability-of-a-multi-strain-postbiotic-to-impact-inflammation-immune-components-gastrointestinal-symptoms-recovery-anxiety-and-intestinal-permeability-100622774","NCT07387991","Evaluating the Ability of a Multi-Strain Postbiotic to Impact Inflammation, Immune Components, Gastrointestinal Symptoms, Recovery, Anxiety, and Intestinal Permeability","Clinical Trial to Evaluate the Ability of Multi-Strain Postbiotic to Impact Inflammation, Immune Components, Gastrointestinal Symptoms, Recovery, Anxiety, and Intestinal Permeability","BIO","Inclusion Criteria:\n\nHealthy males and females aged 18 to 55 years of age. Individual indicates they are physically active defined as: 30 minutes of moderate intensity activity 4 days per week in the past 3 months.\n\nSubject has the ability to exercise on a treadmill without issue or concern. Body Mass Index (BMI) 18.0-32.0 kg\u002Fm2 (normal weight to obesity weight). The average BMI of the entire cohort will be \\\u003C30.0 kg\u002Fm2.\n\nSubject is in good health and appropriate for exercise as determined by physical examination and medical history.\n\nSubject can exercise on a treadmill without issue or concern. Subject is a non-smoker. Subject agrees to not use any new vitamin, mineral, or dietary supplements 24 hours prior to the exercise test visits.\n\nSubject is willing and able to comply with the protocol including: attending the study scheduled appointments, of which two of the study visits may take up to four hours of completion.\n\nSubject agrees to refrain from exercise for the 24 hours prior to any test visits.\n\nSubject agrees to refrain from alcohol use for at least 24 hours before every study visit.\n\nSubject is able to understand and sign the informed consent to participate in the study.\n\nExclusion Criteria:\n\nIndividuals who are determined to have liver, renal, cardiovascular, or other metabolic disease.\n\nUse of any dietary supplements, prescription mediation (particularly antibiotics and\u002For anti-inflammatories), or probiotics within the past 2 months which may confound the study or its endpoints.\n\nAlcohol consumption (\\>2 standard alcoholic drinks\u002Fday or \\>10 drinks\u002Fweek) or drug abuse\u002Fdependence.\n\nSmokers (defined as greater than 2 cigarettes per day for past 90 days). Clinically significant abnormal laboratory results at screening. Allergy or sensitivity to study supplement ingredients. Individuals who are cognitively impaired and\u002For who are unable to give informed consent.\n\nIndividuals with diabetes, asthma, rheumatoid arthritis, colitis, IBS\u002FIBD, gout, or fibromyalgia.\n\nAny other condition which in the PI's opinion may adversely affect the subject's ability to complete the study, its measurement or poses significant risk to the subject.","55 Years",{"count":99,"type":23},50,[26],"This study will evaluate the effects of a multi-strain postbiotic supplement on markers of inflammation, immune function, gastrointestinal symptoms, psychological well-being, and intestinal permeability in healthy adults. The primary objective is to determine whether four weeks of postbiotic supplementation alters physiological and perceptual responses to a standardized bout of moderate-to-high intensity exercise compared with placebo.\n\nApproximately 50 healthy men and women aged 18 to 55 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Participants will be randomly assigned to receive either a multi-strain postbiotic supplement or a matched placebo for 28 days.\n\nAt the end of the supplementation period, participants will complete a 45-minute treadmill exercise bout at 75% of their individually determined maximum heart rate. Blood samples will be collected to assess biomarkers of inflammation, immune activity, and recovery. Gastrointestinal symptoms, intestinal permeability, anxiety, and perceived recovery will be evaluated using validated questionnaires.\n\nThis study is designed to determine whether postbiotic supplementation modulates physiological stress responses and subjective well-being following prolonged exercise in healthy adults.",[103,104],"Inflammation","Gastrointestinal Symptoms","NOT_YET_RECRUITING","2026-01-28",{"date":108,"type":53},"2026-02-04",{"date":110,"type":23},"2026-06-01",{"date":112,"type":23},"2027-06-01",{"name":59,"class":60},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":17,"sex":70,"minAge":19,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":24,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":61},"100622795","impact-of-weizmannia-bacillus-coagulans-jbi-yz63-on-gut-health-and-fecal-microbiome-changes-100622795","NCT07388264","Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","Examining the Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","WIZ","Inclusion Criteria Ages of 18 - 50 years Average daily bloating score \\>5 on question 3 of the Modified daily Abdominal, Gas, and Bloating Questionnaire and\u002For bloating for \\>5 days during the past 14 days Body mass index (BMI) 18.5 - 29.9 kg\u002Fm2 (Inclusive) (Individuals \\>29.9 kg\u002Fm2, but \\\u003C25% fat for men and \\\u003C30% fat for women will be accepted into the study. The cohort average of body mass index will not exceed 29.9 kg\u002Fm2) Weight stable for the past three months (defined as less than a 5% variation in body mass over this time) Determined to be healthy through completion of a health history questionnaire Subject agrees to maintain their existing dietary patterns throughout the study period and to report to study investigators any changes particularly as they relate to probiotic-containing or fermented foods Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.\n\nMinimum baseline physical activity level (defined as at least 30 minutes of moderate intensity exercise at least 4 days per week for the past 3 months) Subject is willing and able to comply with the study protocol. Study participant is not currently enrolled in another clinical trial that involves the administration of some investigative agent Subject has given voluntary, written, informed consent to participate in the study.\n\nExclusion Criteria Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals Has liver disease or some form of clinically diagnosed hepatic impairment Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL) Diagnosed with or is being treated for some form of thyroid disease Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year Diagnosed with some form of immune disorder (i.e., HIV\u002FAIDS) History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n\nParticipant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) Participant has been treated for a gastrointestinal related disorder, complication, or disorder within the past 30 days Positive medical history for any neurological condition or neurological disease Diagnosed with or being treated for any endocrinological disorder or currently used any form of hormone replacement (prescribed\u002Fdoctor ordered or not) Women with a history of hormone-related conditions such as endometriosis, fibroids, polycystic ovary syndrome Currently prescribed for the first time statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months Currently prescribed for the first time hypertension medication (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months Current antibiotic use or other prescription or over-the-counter medications that may impact study outcomes Have a known sensitivity or allergy to any of the study products Blood donation in past 60 days Current smoker (average of \\> 1 pack per week within the past 3 months) or has quit within the past six months. This includes all forms of nicotine They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study Competitive athletes will be excluded History of alcohol or substance abuse in the 12 months prior to screening Current use of anabolic steroids (medically prescribed or otherwise) Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol Report taking a probiotic or other dietary supplement know to impact digestion or gut function in the past 30 days Recent history (\\\u003C3 months) of exercise training or weight loss (\\> 5%) Currently following a ketogenic or low carbohydrate diet within the past 30 days.\n\nWomen who are pregnant, planning to become pregnant, or lactating currently or within the past six months Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data","50 Years",{"count":22,"type":23},[26],"This study will evaluate the effects of supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 on gastrointestinal health in healthy, physically active adults. The primary objective is to determine whether daily intake of this probiotic strain improves symptoms of constipation and related gastrointestinal function compared with placebo.\n\nApproximately 30 healthy men and women aged 18 to 50 years will be enrolled in a randomized, double-blind, placebo-controlled, crossover trial. Participants will complete two 4-week supplementation periods, one with Weizmannia (Bacillus) coagulans JBI-YZ6.3 and one with placebo, separated by a 4-week washout period. The total duration of participation will be approximately 13 to 14 weeks, including screening and testing visits.\n\nGastrointestinal symptoms will be assessed at baseline and after each supplementation period using validated questionnaires, with particular focus on the constipation domain of the Gastrointestinal Symptom Rating Scale (GSRS). Secondary outcomes will include additional gastrointestinal symptom domains and markers of perceived gut comfort and function.\n\nThis study is designed to determine whether supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 produces clinically meaningful improvements in gastrointestinal symptoms in physically active adults compared with placebo.",[104,127,128,129],"Constipation","Gut Health","Gastrointestinal Function",{"date":131,"type":53},"2026-02-05",{"date":133,"type":53},"2025-06-15",{"date":135,"type":23},"2026-06-15",{"name":59,"class":60},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":17,"sex":70,"minAge":19,"maxAge":122,"enrollmentInfo":144,"targetDuration":4,"studyType":24,"phases":146,"briefSummary":147,"conditions":148,"keywords":155,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":61},"100567804","dose-response-impact-of-glucosyl-hesperidin-citrapeak-on-exercise-performance-blood-flow-stress-cognition-and-other-perceptual-indicators-100567804","NCT06672952","Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators","HES","Inclusion Criteria:\n\n1. Participants who are between 18 - 50 years of age\n2. Body mass index values will range from \\>25.0 \\\u003C 30.0 kg\u002Fm2\n3. The average body mass index for entire study cohort will be less than 27.0 kg\u002Fm2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 27.0 kg\u002Fm2\n4. Free-living and independent\n5. In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders\n6. Willingness to maintain consistent sleep duration the evening before study visits\n7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures\n8. Regular completion of at least 180 minutes of moderate to vigorous exercise per week for the past 6 months\n\nExclusion Criteria:\n\n1. Not currently completing at least 180 minutes of moderate to vigorous exercise per week for the past 6 months\n2. Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease\n3. Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals\n4. Has liver disease or some form of clinically diagnosed hepatic impairment\n5. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL)\n6. Diagnosed with or is being treated for some form of thyroid disease\n7. Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year\n8. Diagnosed with some form of immune disorder (i.e., HIV\u002FAIDS)\n9. History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n10. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)\n11. Positive medical history for any neurological condition or neurological disease\n12. Currently prescribed a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.)\n13. Current smoker (average of \\> 1 pack per day within the past 3 months) has quit within the past six months. This includes all forms of nicotine\n14. Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to weight loss such as thermogenics, hydroxycitric acid, ephedra, capsaicin, etc.\n15. Participants who are lactating, pregnant or planning to become pregnant\n16. Have a known sensitivity or allergy to any of the study products\n17. History of alcohol or substance abuse in the 12 months prior to screening\n18. Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol\n19. Any orthopedic limitation that would prevent participation in a general fitness program\n20. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data",{"count":145,"type":23},60,[26],"The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.",[149,150,151,152,153,154],"Exercise Performance","Exercise Recovery","Cognitive Function","Nitric Oxide","Blood Flow","Endurance Exercise",[156,157,158,159,160,161,162,163,164,165],"exercise performance","aerobic capacity","anaerobic power","mood","nitric oxide","cognitive function","glucosyl-hesperidin","training readiness","fuel utilization","endothelial function","2025-12-05",{"date":168,"type":53},"2025-12-12",{"date":170,"type":53},"2025-04-15",{"date":172,"type":23},"2026-01-01",{"name":59,"class":60},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":17,"sex":70,"minAge":19,"maxAge":20,"enrollmentInfo":182,"targetDuration":4,"studyType":24,"phases":184,"briefSummary":185,"conditions":186,"keywords":194,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":219,"locationsCount":61},"100577217","a-randomized-double-blind-study-to-assess-the-effect-of-a-postbiotic-on-oxidative-stress-and-exercise-performance-100577217","NCT06795425","A Randomized, Double-Blind Study to Assess the Effect of a Postbiotic on Oxidative Stress and Exercise Performance","A Randomized, Double-Blinded, Placebo-Controlled, Parallel Study, to Assess the Effect of a Novel Postbiotic Blend on Exercise Induced Oxidative Stress Markers and Exercise Performance","PBE","INCLUSION CRITERIA\n\nTo be eligible for inclusion, the participant must fulfill all of the following criteria:\n\n1. Male or female participants between 18 - 45 years of age\n2. Signed informed consent.\n3. Health, which is defined as currently not being treated for an active cardiac, pulmonary, metabolic, immunological, neurological, respiratory, orthopedic, musculoskeletal, psychiatric, or reproductive disease or disorder. With research team and principal investigator discretion, some ongoing treatments will be permitted if a determination is made that the treatment will not increase risk of study participation and the treatment or illness itself will not confound with desired study outcomes.\n4. Physically active, which is defined as performing aerobic or resistance-based physical exercise between 2 and 5 times per week at a rating of perceived intensity (RPE) of 4 or greater (out of 10)\n5. Body mass index values will range from \\>18.5 to \\\u003C 29.9 kg\u002Fm2 (Inclusive)41 (Weir and Jan 2024).\n6. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures.\n\nEXCLUSION CRITERIA\n\nParticipants will be excluded from the study if they meet any of the following criteria:\n\n1. Body mass index \\\u003C18.5 to \\\u003C29.9 kg\u002Fm2 (Inclusive)\n2. Use of antibiotics or probiotics in the previous 3 months\n3. Positive medical history and\u002For is currently being treated for some form of heart or cardiovascular, neurological impairment, disease or condition, immune disorder or disease, thyroid disease, kidney disease, renal failure, regular dialysis, liver disease or other diagnosed hepatic impairment.\n4. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL)\n5. Diagnosed with major affective disorder or other significant psychiatric disorder or disturbance that required hospitalization or home intervention in the prior year.\n6. History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n7. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, bile acid malabsorption, H.pylori infection, small intestine bacterial overgrowth (SIBO), celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)\n8. Recently prescribed or change in dosage (within the past 6 months) of statin drug (i.e., Lipitor, Livalo, Crestor, Zocor, etc.), hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.), or psychiatric medications.\n9. Consumption (any dose or amount) of any nicotine-containing product (cigarette, cigar, vaping, etc.)\n10. Participants who are lactating, pregnant or planning to become pregnant.\n11. History of alcohol or substance abuse in the 12 months prior to screening\n12. Receipt or use of an investigational product in another research study within 60 days of beginning the study protocol.\n13. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data.\n14. Extensive travel (\\>1 month) that will disrupt original outline of the study protocol.\n15. Participant is consuming a biotic product (pre-, pro-, syn-, or post-) or alters their diet resulting in a change in the amount of prebiotic, probiotic, or fermented foods that are consumed while in the study protocol.",{"count":183,"type":23},80,[26],"This is a prospective, randomized, placebo controlled, double-blind study to assess the effects of a postbiotic blend on exercise induced oxidative stress markers and exercise performance in healthy adult.",[187,188,189,190,191,128,192,149,193],"Oxidative Stress","Healthy","Exercise-induced Muscle Damage","Exercise-induced Muscle Soreness","Immune Function","Microbiome Analysis","Exercise Metabolism",[195,196,197,198,156,199,200,201,202,203,204,205,206,207,208,209,210,211,212],"oxidative stress","antioxidants","postbiotics","ergogenic aid","muscle damage","recovery","gut microbiome","immune function","sleep quality","anxiety","recreationally active","inflammation","endurance training","fecal microbiota","nutritional supplement","aerobic exercise","biomarkers","clinical trial","2025-01-21",{"date":215,"type":53},"2025-01-28",{"date":217,"type":23},"2025-02-01",{"date":172,"type":23},{"name":59,"class":60},""]